Clinical trial
A Study for Participants With Major Depression
NCT00420004 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00420004 |
|---|---|
| Title | A Study for Participants With Major Depression |
| Official title | A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | LY2216684, Placebo, Escitalopram |
| Enrollment | 469 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jan 9, 2007 |
| Last update posted | Apr 27, 2018 |
| Countries | Romania, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: